Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 12 recruiting now early-phase tilt

Endometrial Carcinoma: early-phase trial registry

12 of 28 indexed Endometrial Carcinoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #577 of 28,707 conditions by registered trial count.

28 US clinical trials · 12 currently recruiting · #577 of 28,707 conditions by registered trial count

Endometrial Carcinoma: 28 US clinical trials tracked, 12 recruiting.

Endometrial Carcinoma is the subject of 28 registered US clinical trials on ClinicalTrials.gov, 12 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is Mayo Clinic, running 6 of these trials.

Enrollment posture brief

Registry condition endometrial-carcinoma

OPEN 12 | RECR 43% | LATE 1 | EARLY 15 | RANK #577 | SPON 6

Nearest open-share peer: Acute Myelogenous Leukemia (AML) (43% recruiting · 7 trials)

Endometrial Carcinoma (this)43%Anatomic Stage IB Breast Can25%Carcinoma, Hepatocellular25%Autistic Disorder17.9%Cocaine-Related Disorders0%
Open-enrollment share among volume-matched conditions near Endometrial Carcinoma

Endometrial Carcinoma lists 12 open slots (43% of 28 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Endometrial Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Endometrial Carcinoma is recruiting above its size-band peers.

    12 of 28 indexed trials (42.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Endometrial Carcinoma research.

    Mayo Clinic accounts for 6 of 28 trials (21.4%). 17 distinct sponsors appear on at least one study for this condition label.

  3. Typical Endometrial Carcinoma enrolment sits around 89 participants.

    Median target enrolment is 89 among the 28 trials that report a genuine target (sentinel values excluded). 16 of those (57.1%) plan for fewer than 100 participants.

  4. Endometrial Carcinoma research is mostly interventional.

    20 interventional and 8 observational studies make up this index (71.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 17Phase 28Phase 31

Open and recent trials

28 total, page 1 of 1

RECRUITING Phase 3 360 participants

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

National Cancer Institute (NCI)

NCT05256225

RECRUITING 300 participants

Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding

Mayo Clinic

NCT06365905

RECRUITING Phase 1 147 participants

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Children's Oncology Group

NCT04851119

RECRUITING NA 120 participants

Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer

Mayo Clinic

NCT04567771

RECRUITING NA 120 participants

An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study

Roswell Park Cancer Institute

NCT06855706

RECRUITING Phase 1 113 participants

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Fate Therapeutics

NCT07216105

RECRUITING 100 participants

Molecular and ctDNA Characterization of High-Risk Endometrial Cancer

Mayo Clinic

NCT07062016

RECRUITING 60 participants

Screening and Staging of Benign vs Malignant Pelvic Abnormalities

Mayo Clinic

NCT07407959

RECRUITING Phase 1 60 participants

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

National Cancer Institute (NCI)

NCT06253494

RECRUITING NA 30 participants

Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia

Dana-Farber Cancer Institute

NCT04839614

RECRUITING Early Phase 1 28 participants

A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer

Memorial Sloan Kettering Cancer Center

NCT05691010

RECRUITING Phase 2 27 participants

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Mayo Clinic

NCT07285044

ACTIVE NOT RECRUITING Phase 2 6,452 participants

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

NCT02465060

ACTIVE NOT RECRUITING Phase 1 1,410 participants

Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)

Klus Pharma

NCT04152499

ACTIVE NOT RECRUITING 310 participants

Pelvic Floor Dysfunction and Quality of Life in Uterine Cancer Survivors

M.D. Anderson Cancer Center

NCT04634617

ACTIVE NOT RECRUITING 191 participants

Targeting Inflammation for Endometrial Cancer Prevention

Mayo Clinic

NCT05407025

ACTIVE NOT RECRUITING Phase 1 94 participants

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

National Cancer Institute (NCI)

NCT01366144

ACTIVE NOT RECRUITING 89 participants

Changes in Pelvic Health, Sexual Function, and Quality of Life in Women With Pelvic Cancer Undergoing Radiation Therapy

Ohio State University Comprehensive Cancer Center

NCT04713618

ACTIVE NOT RECRUITING 79 participants

Longitudinal Evaluation of Women Undergoing Pelvic Surgery for the Treatment of Gynecologic Cancer

M.D. Anderson Cancer Center

NCT00791635

ACTIVE NOT RECRUITING Phase 2 51 participants

Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer

Northwestern University

NCT04576104

ACTIVE NOT RECRUITING Phase 2 50 participants

A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma

Yale University

NCT04251416

ACTIVE NOT RECRUITING Phase 2 44 participants

Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy

City of Hope Medical Center

NCT03671811

ACTIVE NOT RECRUITING NA 22 participants

Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer

University of Utah

NCT05139368

COMPLETED Phase 1 150 participants

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

Xencor

NCT03517488

COMPLETED Phase 2 47 participants

Health and Recovery Program in Increasing Physical Activity Level in Stage IA-IIIA Endometrial Cancer Survivors

Stanford University

NCT03367923

COMPLETED 40 participants

Dosimetric Analysis of Vaginal Cuff Brachytherapy in Endometrial Carcinoma

Dana-Farber Cancer Institute

NCT00165126

COMPLETED Phase 2 35 participants

A Study of Nivolumab in Selected Uterine Cancer Patients

Memorial Sloan Kettering Cancer Center

NCT03241745

COMPLETED Phase 2 22 participants

Trial of Maintenance With Niraparib- Uterine Serous Carcinoma

Northwell Health

NCT04080284

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 8
Phase 3 1

Named interventions

Most-linked intervention names on Endometrial Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Questionnaire Administration Other
7 trials
Biospecimen Collection Procedure
4 trials
Paclitaxel Drug
3 trials
Non-Interventional Study Other
3 trials
Quality-of-Life Assessment Other
3 trials
Carboplatin Drug
3 trials
Megestrol Acetate Drug
2 trials
Biopsy Procedure Procedure
2 trials

US sites by state

Facility locations filed on Endometrial Carcinoma trials. A trial with sites in several states counts in each.

California 8 trials
Texas 7 trials
New York 7 trials
Minnesota 7 trials
Florida 6 trials
Pennsylvania 5 trials
Massachusetts 5 trials
Arizona 5 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Endometrial Carcinoma page

28 registered trials, 12 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 12 Endometrial Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Mayo Clinic sponsors the most Endometrial Carcinoma trials on record, review their full trial history before evaluating a specific study. See Mayo Clinic's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Endometrial Carcinoma condition card totals 28 registered trials; most-linked intervention Questionnaire Administration; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.